Skip to main content

Table 4 Indicators of therapeutic potentials of protoplast Fusant-06 l-ASNase

From: Production, characterization and techno-economic evaluation of Aspergillus fusant l-asparaginase

Strain

Cell line

IC50 (µg/mL)

SI

Adjusted r2

RMSE

Fusant

 

1.055

77.13

0.9775

4.782

Ile−Thr−Asp-C-180-K

HL-60

3.178

27.66

0.9879

1.739

Val−Asp-S-180-E

 

19.738

4.98

0.9877

0.763

Fusant

 

6.359

12.80

0.9865

4.035

Ile−Thr−Asp-C-180-K

HepG-2

9.392

9.36

0.9648

3.119

Val−Asp-S-180-E

 

22.683

4.34

0.9463

0.872

Fusant

 

9.446

8.61

0.9910

3.528

Ile−Thr−Asp-C-180-K

MCF-7

11.831

7.43

0.9934

1.928

Val−Asp-S-180-E

 

25.458

3.86

0.9884

2.172

Fusant

 

81.370

–

0.9670

2.905

Ile−Thr−Asp-C-180-K

HEK-238 T

87.890

–

0.9898

1.283

Val−Asp-S-180-E

 

98.361

–

0.9789

1.663

  1. HL-60 Human myeloid lymphoma, HepG-2 Hepatocellular carcinoma, MCF-7 Human breast carcinoma